drugset / Trial / NCT00310492

Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis

NCT00310492 ↗

Phase 3 Completed 154 enrolled ALK-Abelló A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is performed to assess the efficacy and safety of ALK-depot SQ mites for treatment of atopic dermatitis

Timeline

Start
2006-04
Primary completion
2009-05
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator ALK-depot SQ mites Unknown 100000 unknown Subcutaneous

Indications